Ignite Creation Date:
2024-05-06 @ 12:41 AM
Last Modification Date:
2024-10-26 @ 10:53 AM
Study NCT ID:
NCT01638572
Status:
COMPLETED
Last Update Posted:
2012-07-11
First Post:
2012-07-08
Brief Title:
Exploring the Possibility to Use Glycosyltransferase as a Prognosis Marker of Neuroblastoma
Sponsor:
National Taiwan University Hospital
Organization:
National Taiwan University Hospital
Study Overview
Official Title:
Exploring the Possibility to Use Glycosyltransferase as a Prognosis Marker of Neuroblastoma
Status:
COMPLETED
Status Verified Date:
2012-06
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
Well-regulated glycosylation is essential for the normal development of the nervous system Altered expression of glycosyltransferases with resulting dysregulated glycosylation of neuroblastic cells might lead to the development of NB The β14-N-acetylgalactosaminyltransferase III B4GALNT3 exhibits GalNAc transferase activity to form the GalNAcβ14GlcNAc LacdiNAc or LDN structure The Drosophila B4GALNTA homolog of human B4GALNT3 has been suggested to regulate the neuronal development By immunohistochemical studies we demonstrated that the expression of B4GALNT3 correlated well with histological grade of differentiation in NB tumor samples Since well differentiated tumors usually carry a better prognosis we thus speculate that expression of B4GALNT3 in tumor tissues can a favorable prognostic factor of NB
To explore the role of B4GALNT3 in the prognosis of NB we propose the following project with two specific aims
Aim Ⅰ Establishing the significance of B4GALNT3 in the prognosis of NB We plan to collect 90 NB tumor samples and evaluate the RNA and protein expression levels by Q-PCR Western blot and immunohistochemistry in the tumor samples The results will be compared with the other clinicopathological and biological factors of NB Also the expression levels of B4GALNT3 in tumor tissues will be correlated to the patients outcome to clarify whether B4GALNT3 could be a prognosis marker of NB
Aim II Clarifying the effects of B4GALNT3 on NB cell behavior in vitro and in vivo For further strengthening the prognostic role of B4GALNT3 in NB NB cell phenotype and behavior changes after overexpression or knock-down of B4GALNT3 are evaluated by in vitro assays as well as by a nude mice xenograft model
In summary if our project can establish the role of B4GALNT3 expression in NB we may further subclassify the NB patients and give the NB patients more appropriate therapies to improve patients outcome Furthermore B4GALNT3 could potentially serves as a therapeutic target in the future
To explore the role of B4GALNT3 in the prognosis of NB we propose the following project with two specific aims
Aim Ⅰ Establishing the significance of B4GALNT3 in the prognosis of NB We plan to collect 90 NB tumor samples and evaluate the RNA and protein expression levels by Q-PCR Western blot and immunohistochemistry in the tumor samples The results will be compared with the other clinicopathological and biological factors of NB Also the expression levels of B4GALNT3 in tumor tissues will be correlated to the patients outcome to clarify whether B4GALNT3 could be a prognosis marker of NB
Aim II Clarifying the effects of B4GALNT3 on NB cell behavior in vitro and in vivo For further strengthening the prognostic role of B4GALNT3 in NB NB cell phenotype and behavior changes after overexpression or knock-down of B4GALNT3 are evaluated by in vitro assays as well as by a nude mice xenograft model
In summary if our project can establish the role of B4GALNT3 expression in NB we may further subclassify the NB patients and give the NB patients more appropriate therapies to improve patients outcome Furthermore B4GALNT3 could potentially serves as a therapeutic target in the future
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None